Last checked at 
LONDON (Alliance News) - Physiomics PLC on Wednesday said it will use the opportunity of an upcoming conference to meet with current as well as potential future clients.
Shares in the technology solutions provider to the biopharma industry were trading down 8.9% at 3.24 pence each.
The company will attend the American Academy of Cancer Research annual meeting 2019, taking place in Atlanta, Georgia at the end of March, where it will present two posters and also have a "significant presence" including a stand in the meeting hall.
Of the posters to be presented, Physiomics will show its first tool based on artificial intelligence technology for precision dosing of docetaxel in prostate cancer.
"Currently dosing of docetaxel in prostate cancer is based on population averages, leading to effective under or overdosing in a significant number of patients," Physiomics said. "Our tool could, if approved, provide information that could assist clinicians in adapting chemotherapy dosing for individual patients."
Furthermore, the company will also present its Virtual Tumour technology as a tool to help clients understand the likely response of tumours to drug treatments.
"The most recent evolution of Virtual Tumour has been to enhance its ability to model the longer-term re-growth of clinical tumours which can exhibit widely varying times to re-growth/ progression following irradiation," the company added.
